![[ Visit Client Website ]](images/banner.JPG)
Friday, May 16, 2008
Champagne Terrace/Bordeaux (Novotel London West)
Background: The occurrence of autism has also been discussed in many cases as a consequence of inflammatory processes.The treatment of PDD related behavioral problems with atypical antipsychotics show considerably good effectiveness with more favorable side effect profile. However, antipsychotics in treatment of PDD spectrum, in general act as syndrome oriented therapy and less as a causal therapy. All patients with autism have some core symptoms such as poor social interaction and relationship, verbal and nonverbal communication difficulties, limited interests in activities or play. All mentioned symptoms are based in specific behavioral problems of autism. With early and intensive treatment, most children improve their ability to relate to others, communicate, and help themselves
Objectives: The study was based on the idea that substances with immunomodulatory properties could be used for the treatment of psychiatric disorders such as autism.
Methods: We have worked on 6 children who were from 6 to 8 year old (4 boys and 2 girls) with significant bihavioral problems in PDD spectrum. All the patients before participating in study had received risperidon 1- 4 mg. However, due to the lack of effects , the treatment was discontinued. After two weeks of washout, combination of Ziprasidone (Geodon® 20 mg – minimal dose) and Meloxicam, (Movalis ® 3,7 mg- minimum dose) was administrated. Behavior assessment based in symptoms estimation by parents and other caregivers was made at the end of 3 week of the treatment. Simultaneously our team estimated the patients using CGI scale. Results: Significant improvement was registered among 4 out 6 children. No side effects were observed.
Conclusions: Combination of atypical and COX-2 inhibitors may be promising for treatment of behavioral disorders among children with autistic spectrum. However more comprehensive study is needed.
Objectives: The study was based on the idea that substances with immunomodulatory properties could be used for the treatment of psychiatric disorders such as autism.
Methods: We have worked on 6 children who were from 6 to 8 year old (4 boys and 2 girls) with significant bihavioral problems in PDD spectrum. All the patients before participating in study had received risperidon 1- 4 mg. However, due to the lack of effects , the treatment was discontinued. After two weeks of washout, combination of Ziprasidone (Geodon® 20 mg – minimal dose) and Meloxicam, (Movalis ® 3,7 mg- minimum dose) was administrated. Behavior assessment based in symptoms estimation by parents and other caregivers was made at the end of 3 week of the treatment. Simultaneously our team estimated the patients using CGI scale. Results: Significant improvement was registered among 4 out 6 children. No side effects were observed.
Conclusions: Combination of atypical and COX-2 inhibitors may be promising for treatment of behavioral disorders among children with autistic spectrum. However more comprehensive study is needed.